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Positron Emission Tomography/Computed Tomography
and Lymphovascular Invasion Predict Recurrence in Stage I
Lung Cancers
Satoshi Shiono, MD, PhD, Masami Abiko, MD, PhD, and Toru Sato, MD, PhD
Background: Although pathologic stage I lung cancers generally
have a favorable prognosis, approximately 20% of patients experi-
ence recurrence after surgery. Therefore, a method of selecting
patients who need adjuvant therapy is necessary. The goal of this
study was to evaluate the significance of positron emission tomog-
raphy (PET)/computed tomography (CT) results after lung cancer
surgery and to identify the predictive factors for recurrence in cases
of pathologic stage I lung cancer.
Methods: From January 2004 to December 2008, 356 patients with
lung cancer underwent surgery at our institution. Of these, 282
patients received F-18 fluorodeoxyglucose PET/CT, and the maxi-
mum standardized uptake value (max SUV) was measured. There
were 201 patients with pathologic stages IA and IB evaluated. The
associations between disease-free survival (DFS) and the following
clinicopathological factors were analyzed: age, gender, smoking
history, carcinoembryonic antigen level, tumor size, max SUV
values, histology, and lymphovascular and pleural invasion.
Results: The 4-year DFS rate was 86.3%. Multivariate analysis
revealed lymphovascular invasion (LVI; p  0.01) and max SUV
4.7 (p  0.01) to be independent predictive factors. Patients
with a max SUV more than 4.7 had a significantly high risk of
recurrence. DFS of patients with high max SUVs and LVI (n 
18) was significantly reduced compared with other patients (n 
183, p  0.01).
Conclusions: The PET-CT results significantly correlated with
recurrence in pathologic stage I lung cancers. Patients with high max
SUVs and LVI were more likely to have recurrence and should be
candidates for adjuvant chemotherapy.
Key Words: Lung cancer, PET/CT, Lymphovascular invasion,
Recurrence.
(J Thorac Oncol. 2011;6: 43–47)
F-18 Fluorodeoxyglucose (FDG) positron emission tomog-raphy (PET) has become an important tool in staging
patients with non-small cell lung cancer (NSCLC).1 Recent
studies have shown that the rate of FDG uptake by the
primary NSCLC site correlated with tumor aggressiveness
and that the standardized uptake value (SUV) was a signifi-
cant prognostic factor in surgically resected patients with
lung cancer,2–9 even in early-stage bronchioloalveolar carci-
noma.10,11 The FDG SUV may be a powerful surrogate
marker for outcome in NSCLC. Nevertheless, it remains
unclear whether the SUV is an independent prognostic factor
compared with stage and performance status.6 In addition,
there has been no standardization of FDG-PET images, and
the extent of its limitations has not been clarified.
Analysis of data from a Japanese Lung Cancer Registry
study revealed that pathologic stage I NSCLC accounted for
59% of lung cancer cases. Although the 5-year survival of
pathologic stage IA lung cancer is 83.9% in Japan,12 approx-
imately 20% of these patients develop recurrence after sur-
gery.13,14 Although studies using platinum-based doublets did
not show a survival advantage in stage I lung cancer, Japa-
nese postoperative adjuvant chemotherapy for stage I adeno-
carcinoma was associated with improved survival15,16; there-
fore, a method for selecting patients who need adjuvant
therapy is necessary.
This study was conducted to evaluate the significance
of PET/computed tomography (CT) results after lung cancer
surgery, and, with the use of multivariate analysis, to identify
predictive factors for recurrence, including pathologic fac-
tors, in patients with pathologic stage I lung cancer. Accurate
markers would be helpful in stratifying patients for therapy
and in predicting outcomes.
PATIENTS AND METHODS
This retrospective study was performed from January
2004 to December 2008. The following information was
prospectively collected: age at diagnosis, gender, smoking
status, serum carcinoembryonic antigen (CEA) level, time of
surgery, tumor-node-metastasis staging,17 maximum (max)
SUV of primary tumor, extent of surgery, pathologic find-
ings, time to recurrence, time to last follow-up, time to death,
and cause of death. Study inclusion criteria were as follows:
(1) complete resection, (2) no induction therapy, (3) preop-
erative PET/CT, and (4) no severe diabetes (requiring insulin
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therapy). Patients with pure ground-glass opacity were ex-
cluded from the study, because these cases have low FDG
uptake and apparently different biologic behavior.11 Preoper-
ative diagnosis was obtained by bronchoscopy, but if preop-
erative diagnosis was not obtained, diagnosis by frozen sec-
tion was obtained during surgery. Mediastinoscopy was not
routinely performed. During the study period, 356 patients
underwent surgery for lung cancer, and 201 eligible patients
with pathologic stage IA and IB disease were analyzed.
Regarding patient follow-up after surgery, we examined pa-
tients every 3 to 4 months in the outpatient clinic and
performed annual CT. If patients complained of clinical
symptoms, imaging was performed.
After discussion by a multidisciplinary team, a PET/CT
was requested for appropriate patients, and PET/CT was
referred to nearby hospital for the procedure. After the im-
ages were viewed by two radiologists, the images were also
viewed by the multidisciplinary team. PET imaging was
performed in routine clinical fashion in accordance with
standard protocol. Before the scan, each patient fasted for 6
hours. A standard dose of FDG, 3.75 MBq/kg was adminis-
tered intravenously, and 60 minutes later, PET and CT
images were obtained using a Discovery LS PET/CT system
(GE Healthcare, Milwaukee, WI). Scanning was performed
from the base of the skull to the level of the midthigh.
Intravenous contrast medium was not used for PET/CT scan-
ning. To determine the max SUV after images were obtained,
the region of interest, which was established by the radiolo-
gists, was manually placed over the tumor site on each
transaxial slice. The max SUV was then automatically cal-
culated by software for each slice. The highest max SUV was
used in our analysis.
Resected specimens were fixed in 10% formalin and cut
into 5 to 10 mm slices. Sections containing tumor tissue were
embedded in paraffin, and consecutive 5 m sections were
stained using hematoxylin and eosin or elastica-Masson.
The Ethics Committee of our institution approved this
study and waived the need for informed consent from patients
as long as patient data remained anonymous. No financial
support was received from companies that make PET/CT
scanners.
Statistical Analysis
Because stage I lung cancers are reported to have a
better prognosis than other lung cancers, special emphasis
was placed on investigating the differences between risk
factors and disease-free survival (DFS) in this study. To
determine the appropriate prognostic max SUV, the patients
were subdivided into two cohorts using receiver operating
characteristic (ROC) curve analysis.18 Overall survival and
DFS were analyzed using the Kaplan-Meier method, and
differences in variables were calculated by the log-rank test.
The date of surgery was defined as the starting point. Time to
recurrence was defined as time from the date of surgery to
recurrence of lung cancer. Patients without recurrence were
censored from the analysis at the time of last negative
follow-up, and patients who died without evidence of recur-
rence were also censored. Cox proportional hazards regres-
sion analysis was used to analyze the data using StatView 5.0
software (SAS Institute Inc., Cary, NC). Statistical signifi-
cance was assumed for p values less than 0.05.
RESULTS
During the study period, there were 147 patients with
pathologic stage IA and 54 with stage IB cancer, ranging in
age from 32 to 86 years (mean, 68 years). There were 122
men and 79 women, and tumor sizes ranged from 0.6 to 5.0
cm (mean, 2.4 cm). Histopathological findings of the tumors
were as follows: adenocarcinoma (n  146), squamous cell
carcinoma (n  39), large cell carcinoma (n  6), adeno-
squamous cell carcinoma (n  5), small cell carcinoma (n 
3), and carcinoid (n  2). Surgical procedures included
lobectomy in 157 cases (78.1%), wedge resection in 27 cases
(13.4%), segmentectomy in 15 cases (7.5%), bilobectomy in
one case (0.5%), and bronchial resection in one case (0.5%).
Twenty-nine patients received adjuvant chemotherapy (ura-
cil-tegafur, n  23; carboplatin/paclitaxel, n  2; and cispla-
tin/etoposide, n  1). Max SUVs ranged from 0 to 24.8
(median, 4.6).
The median follow-up time for surviving patients was
24 months (range, 0–53 months), and the overall 4-year
survival rate after surgery was 83.0%. There was one peri-
operative death due to sepsis (0.5%) and 16 patients (8.0%)
with recurrences after surgery. Median time range of recur-
rence was 22 months (range, 0–51 months), and recurrence
was confirmed by CT or PET/CT. The recurrence sites in
these patients were as follows: brain in four patients, bone in
four, lung in three, mediastinal lymph node in two, adrenal
gland in one, liver in one, and pleura in one. The ROC curve
and the Youden index identified an optimal SUV cutoff value
of 4.7 for lung cancer recurrence (Figure 1).19
The 4-year DFS rate was 86.3%. Univariate analysis
determined that CEA more than 5.0 ng/ml (p  0.02), max
SUV 4.7 (p  0.01), and lymphovascular invasion (LVI;
p  0.01) were significant predictive factors for recurrence
FIGURE 1. Receiver operating characteristic curve analysis
and the Youden index identified an optimal max standard-
ized uptake value (SUV) cutoff value of 4.7 for predicting
recurrence.
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(Table 1). Multivariate analysis determined that LVI (p 
0.01) and max SUV 4.7 (p  0.01) were independent
predictive factors for recurrence (Table 2).
Because high max SUV and LVI could be considered
significant predictive factors for recurrence, the patients were
divided into the following four groups for further analysis:
max SUV 4.7 with LVI (n  18), SUV 4.7 without LVI
(n  82), SUV less than 4.7 with LVI (n  7), and SUV less
than 4.7 without LVI (n  94). Survival of the patients with
high max SUVs and LVI was significantly worse (p  0.01;
Figure 2).
DISCUSSION
In this study, we demonstrated that postoperative re-
currence of stage I lung cancer can be more precisely pre-
dicted by combining imaging and pathologic findings. In this
study, we examined the relationships between features of
those patients and DFS as a primary end point. Predictive
factors for recurrence are not directly related to prognosis, but
predictive factors for recurrence are clearly related to post-
operative prognosis in resected patients with lung cancer. To
identify patients at high risk for recurrence, so that they are
treated with adjuvant chemotherapy, identification of recur-
rence risk factors is needed. Interestingly, oral uracil-tegafur
chemotherapy has been reported to increase the overall 5-year
survival of stage IA vascular invasion patients.14 Among
resected patients with lung cancer, those with high SUVs and
LVI may derive benefit from adjuvant chemotherapy.
Meta-analysis results have demonstrated that patients
with tumors demonstrating higher metabolic activity by SUV
have shorter survivals than patients with tumors with lower
glucose metabolic rates.20 The max SUV is the most fre-
quently evaluated prognostic factor; however, some research-
ers have dichotomized patients using the median SUV. Other
studies comparing differences between survival curves chose
the value maximizing log-rank test results as an SUV thresh-
old, but this method may have high risk for false-positive
results.6 In this study, we normalized SUV according to body
weight and identified the cutoff point by ROC curve analysis.
As previous reports have shown, tumor size, differen-
tiation grade, clinical N status, CEA, vascular invasion, and
surgical curability are regarded as significant prognostic fac-
tors in stage I lung cancer.21,22 In this study, we have
demonstrated that LVI is a significant risk factor for recur-
rence. Tsuchiya et al.14 have shown that the 5-year overall
survival of stage IA patients with vascular invasion was
FIGURE 2. Disease-free survival curves based on four
groups obtained by the patients according to max standard-
ized uptake value (SUV) and lymphovascular invasion (LVI).
TABLE 1. Clinical Factors and Disease-Free Survival
(Univariate Analysis)
Clinical Factors n (%) % 4-yr DFS p
Gender
Male 122 (60.7) 80.4 0.08
Female 79 (39.3) 94.9
Age (yr)
75 52 (25.8) 79.5 0.17
75 149 (74.1) 88.3
Smoker
Yes 120 (59.7) 80.0 0.07
No 81 (40.3) 95.0
CEA (ng/ml)
5.0 41 (20.4) 77.7 0.02
5.0 160 (79.6) 88.5
Max SUV
4.7 100 (49.8) 73.8 0.01
4.7 101 (50.2) 97.6
Tumor size
3.0 50 (24.9) 74.3 0.54
3.0 151 (75.1) 88.9
Histology
Ad 146 (72.6) 86.8 0.50
Non-Ad 55 (27.4) 86.1
LV invasion
Yes 25 (12.4) 72.1 0.01
No 176 (87.6) 88.2
P invasion
Yes 33 (16.4) 76.0 0.36
No 168 (83.6) 88.9
DFS, disease-free survival; CEA, carcinoembryonic antigen; max SUV, maximum
standardized uptake value; Ad, adenocarcinoma; LV, lymphovascular; P, pleural.
TABLE 2. Predictive Factors After Surgery (Multivariate
Analysis)
Variables Risk Ratio 95% CI p
Gender (F/M) 0.61 0.02–22.9 0.79
Age (75/75), yr 2.05 0.69–6.09 0.20
Smoker (yes/no) 1.30 0.04–43.3 0.88
CEA (5.0/5.0 ng/ml) 2.30 0.77–6.92 0.14
Max SUV (4.7/4.7) 20.7 2.59–166 0.01
Tumor size (3.1/3.1 cm) 0.84 0.25–2.79 0.78
Histology (non-Ad/Ad) 0.35 0.10–1.28 0.11
LV invasion (yes/no) 4.83 1.54–15.2 0.01
P invasion (yes/no) 1.00 0.30–3.32 0.99
CEA, carcinoembryonic antigen; max SUV, maximum standardized uptake value;
Ad, adenocarcinoma; LV, lymphovascular; P, pleural.
Journal of Thoracic Oncology • Volume 6, Number 1, January 2011 PET/CT in Stage I Lung Cancers
Copyright © 2010 by the International Association for the Study of Lung Cancer 45
almost similar to that of patients with stage IB NSCLC.
Bodendorf demonstrated that patients with vascular invasion
had a significantly poor prognosis, although lymphatic inva-
sion was not a prognostic factor.23 In addition, lymphatic
vessel invasion has been reported to be associated with
survival.24 To reduce confusion in pathologic diagnosis and
simplify subgrouping, one previous study evaluated as a
single prognostic factor, the combination of lymphatic and
vascular invasion.14 In this study, LVI, the combination of
lymphatic and vascular invasion, was also used. We found
vascular invasion in eight cases (4%) and lymphatic invasion
in 20 cases (10%), results similar to those in another study on
stage IA lung NSCLC, where 8.8% of cases had vascular
invasion and 7.4% had lymphatic invasion.25 We did not
evaluate LVI by immunohistochemical staining, and if it had
been used, there might have been a higher percentage of LVI
seen in our study.
There are some limitations to this study. First, although
we prospectively collected patient data, this study was a
retrospective single-institutional study with low statistical
power. The advantage of a single-institutional study is rigor-
ous patient follow-up. Each patient was seen in our outpatient
clinic every 3 or 4 months, allowing rapid clinical detection
of changes in patient status. In particular, for lung cancer
recurrence, we think that a single-institutional study can more
precisely determine patient status than a multiinstitutional
study. Second, SUV is affected by many factors, and there is
no standard SUV cutoff. Moreover, SUV estimates show
poor reproducibility.6 Although some investigators have been
trying to standardize PET for use in multicenter trials,26 use
of the same SUV cutoff point in multicenter studies still
needs evaluation. Additional studies are needed for arriving
at a universal consensus for the SUV cutoff point. Finally, the
sensitivity, specificity, and accuracy of PET for lung nodules
with ground-glass opacity were significantly lower than for
PET values for solid nodules.27 Because low cellularity and
high mucin content were reported as causes of low 18F-FDG
uptake in mucinous adenocarcinoma,28 PET evaluation of
mucinous adenocarcinoma is also difficult. This type of lung
cancer has been well investigated, and high-resolution CT
provides sufficient information regarding its characteristics.
We believe that PET is a more useful technology for evalu-
ating solid lung cancers.
In summary, because SUV is affected by various
parameters, the use of SUV as a predictive factor for
recurrence may be controversial. Although data in this
study were obtained after a short follow-up period, we
found that PET-CT results were significantly correlated
with recurrence in pathologic stage I lung cancers. In
addition, we determined that patients with a high max SUV
and LVI were more likely to have recurrence. Patients with
high max SUVs and LVI identified by postoperative as-
sessments, even patients with pathologic stage I NSCLC,
may be considered good candidates for adjuvant chemo-
therapy. We believe that PET-CT and pathologic findings
will optimize the identification of stage I patients at higher
risk for recurrence.
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